8-K: Surgery Partners Rejects Bain Capital Buyout, Reaffirms Strong 2025 Guidance and Independent Growth Path

Surgery Partners, Inc. announced that its independent committee concluded discussions with Bain Capital, determining that the company's prospects as an independent public entity exceed the value of Bain Capital's acquisition proposal, while reaffirming its full-year 2025 financial guidance.

Summary

• Surgery Partners, Inc. (SGRY) and Bain Capital Private Equity, LP have concluded discussions regarding Bain Capital's non-binding proposal to acquire all outstanding shares of Surgery Partners not already owned by Bain Capital.
• A Special Committee of independent directors, with the assistance of independent financial and legal advisors, determined that the Company's prospects to deliver long-term growth and value creation as an independent publicly traded company exceeded the value of the Proposal.
• The Board of Directors reaffirms its confidence in the Company's long-term growth prospects and its ability to continue implementing its established long-term growth algorithm and disciplined business execution.
• The Company reiterated its full-year 2025 financial guidance, expecting revenues to be in the range of $3.30 billion to $3.45 billion and Adjusted EBITDA to be in the range of $555 million to $565 million.
• Surgery Partners expects to host an Investor Day in the second half of 2025 to discuss its future growth plans and long-term outlook.

Sentiment

Score: 8

Explanation: The sentiment is highly positive. The company rejected a buyout offer, indicating strong internal confidence in its independent growth prospects. It reaffirmed robust financial guidance for 2025, citing strong Q1 performance and favorable industry trends. Management and even Bain Capital expressed optimism about the company's future.

Positives

• The Independent Committee determined that Surgery Partners' prospects for long-term growth and value creation as an independent publicly traded company exceeded the value of Bain Capital's acquisition proposal.
• The Board reaffirms its confidence in the Company's long-term growth prospects and ability to enhance shareholder value.
• The Company reiterated its full-year 2025 revenue guidance of $3.30 billion to $3.45 billion.
• The Company reiterated its full-year 2025 Adjusted EBITDA guidance of $555 million to $565 million.
• Strong first quarter performance gives the Company confidence in achieving its full-year 2025 guidance.
• Management notes favorable surgical trends and a bullish outlook on the regulatory landscape.
• Surgery Partners is described as a unique, scaled platform in the high-growth outpatient surgical care market.
• The Company leverages a proven joint venture model, strong M&A track record, and favorable demographic and policy tailwinds.
• Bain Capital remains optimistic about Surgery Partners' business, leadership team, and growth strategy, and intends to continue as a long-term investor and collaborator.

Risks

• Reductions in payments from government health care programs and private insurance payors.
• Ability to contract with private insurance payors.
• Changes in payor mix or surgical case mix.
• Failure to maintain or develop relationships with physicians on beneficial or favorable terms.
• Impact of payor controls designed to reduce the number of surgical procedures.
• Challenges in integrating operations of acquired or developed businesses and surgical facilities, attracting new physician partners, or acquiring additional surgical facilities.
• Supply chain issues, including shortages or quality control issues with surgery-related products, equipment and medical supplies.
• Competition for physicians, nurses, strategic relationships, acquisitions and managed care contracts.
• Ability to attract and retain qualified health care professionals.
• Ability to enforce non-compete restrictions against physicians.
• Ability to manage material liabilities incurred as a result of acquiring or operating surgical facilities.
• Impact of future legislation and other health care regulatory reform actions.
• Ability to comply with current health care laws and regulations.
• Outcome of legal and regulatory proceedings.
• Impact of cybersecurity attacks or intrusions.
• Changes in regulatory, economic and other conditions of the states where surgical facilities are located.
• Company's indebtedness.
• Social and economic impact of a pandemic, epidemic or outbreak of a contagious disease on the business.
• Disruptions from weather events and other natural disasters, including hurricanes.

Future Outlook

Surgery Partners expects to continue its long-term growth algorithm and disciplined business execution as an independent publicly traded company. The company anticipates favorable surgical trends and a bullish regulatory landscape. It plans to host an Investor Day in the second half of 2025 to detail its go-forward strategy, provide an outlook on key industry trends, and outline plans to maximize portfolio performance, advance its M&A pipeline, and drive operational efficiencies. The company also reiterated its full-year 2025 revenue and Adjusted EBITDA guidance.

Management Comments

• "Surgery Partners offers a unique, scaled platform in the high-growth outpatient surgical care market that leverages its proven joint venture model, strong M&A track record, and favorable demographic and policy tailwinds. Following review of the Proposal and discussions with Bain Capital, the Independent Committee concluded that the best path forward for Surgery Partners and its stockholders is to continue operating as an independent publicly traded company. We remain confident in the management teams ability to continue delivering sustained growth and significant stockholder returns." Brent Turner, Chairman of the Independent Committee.
• "Our strong first quarter performance gives us even more confidence in our ability to achieve our full-year 2025 revenue and Adjusted EBITDA guidance, reinforcing that Surgery Partners is well positioned to deliver results that support our long-term growth algorithm. Given favorable surgical trends and our bullish outlook on the regulatory landscape, we continue to be excited by Surgery Partners unique competitive positioning and growth potential. As we focus on building upon our strong track record of industry-leading earnings growth and consistent execution, we look forward to continuing our productive relationship with Bain Capital as we pursue our shared goal of delivering long-term value." Eric Evans, CEO of Surgery Partners.
• "While we were not able to agree to terms of a transaction, we remain tremendously optimistic about the business, leadership team, and growth strategy of Surgery Partners. We look forward to continuing to work with Surgery Partners as long-term investors and collaborators." Andrew Kaplan and Devin O'Reilly, Bain Capital Partners.

Industry Context

This announcement highlights the continued growth and attractiveness of the outpatient surgical care market, where Surgery Partners operates a scaled platform. The company's focus on joint ventures and M&A aligns with broader trends in healthcare consolidation and efficiency. The mention of "favorable demographic and policy tailwinds" suggests a positive environment for the sector, driven by an aging population and shifts towards more cost-effective outpatient procedures. The reaffirmation of guidance amidst a rejected buyout offer suggests strong internal confidence in the company's ability to capitalize on these industry trends independently.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or results to assess against global benchmarks. It only states that Surgery Partners is "one of the largest and fastest growing surgical services businesses in the country" with "more than 200 locations in 30 states."

Stakeholder Impact

• Shareholders: The decision to remain independent suggests a belief in greater long-term value creation than the buyout offer, potentially leading to higher future stock prices. Reaffirmed guidance provides stability and confidence.
• Employees: Continued operation as an independent entity likely means stability and continuity for employees, without the disruption of a change in ownership.
• Customers (Patients/Physicians): Continued focus on growth and operational efficiencies could lead to enhanced services and partnerships.
• Creditors: Reaffirmed financial guidance and confidence in future growth may reassure creditors regarding the company's financial health.
• Bain Capital: Will continue as a long-term investor and collaborator, indicating an ongoing relationship despite the rejected buyout.

Next Steps

• Continue operating as an independent publicly traded company.
• Host an Investor Day in the second half of 2025.
• Present go-forward strategy for the business at Investor Day.
• Provide an outlook on key industry trends at Investor Day.
• Detail plans to maximize portfolio performance at Investor Day.
• Advance M&A pipeline.
• Drive operational efficiencies.

Key Dates

Recommendation

Keywords

Healthcare services, Outpatient surgical care, Ambulatory surgery centers, Surgical hospitals, Multi-specialty physician practices, Urgent care facilities, SEC filing, 8-K, SGRY, Surgery Partners, Bain Capital, Private equity, Financial guidance, Adjusted EBITDA, Revenue, Investor Day, Corporate governance, M&A